Purpose: To investigate the effects, and their reversibility, of multiple oral voriconazole doses on a variety of visual tests in healthy male volunteers. Methods: Single-center, double-blind, randomized, placebo-controlled, parallel-group study in 36 volunteers who received voriconazole (n = 18, 400 mg every 12 h on day 1, then 300 mg every 12 h for 27.5 days) or matched placebo (n = 18). Electroretinograms (ERGs) and ophthalmological examinations were performed at screening, throughout the study and at follow-up. Results: Fifteen (83.3%) volunteers treated with voriconazole experienced ≥1 treatment-related visual adverse events (AEs); these included enhanced visual perceptions, blurred vision, color vision changes and photophobia. No serious AEs were reported. Voriconazole reduced from baseline scotopic maximal a- and b-wave amplitude, shortened implicit time and decreased oscillatory potential amplitude compared with placebo. Under photopic conditions, the 30-Hz flicker response amplitude was significantly reduced and was accompanied by a slight but nonsignificant prolongation of peak time. These effects did not progress in degree over the treatment period, and mean changes from baseline in ERG parameters were similar to placebo by day 43 (14 days after end of treatment). In the first week, color vision discrimination was impaired in the tritan axis, although this resolved by end of treatment and was similar to placebo by day 43. Mean deviation in the static visual field indicated increased sensitivity following voriconazole treatment, correlating with decreased amplitude in conjunction with shortened implicit time. Conclusions: Effects of voriconazole on altered visual perception, ERG, color vision and static visual field thresholds are nonprogressive over a treatment period and reversible. It is hypothesized that voriconazole has a pharmacological effect on rod and cone pathways including a possible mechanism of disinhibition that reversibly puts the retina in a more light-adapted state and leads to increased relative contrast sensitivity.

Keywords:
Voriconazole, Antifungal, Electroretinogram, Vision, Retina, Enhanced visual perceptions, Blurred vision, Photophobia
1.
Boucher HW, Groll AH, Chiou CC, Walsh TJ: Newer systemic antifungal agents: pharmacokinetics, safety and efficacy. Drugs 2004;64:1997-2020.
2.
Florea NR, Kuti JL, Quintiliani R: Voriconazole. A novel azole antifungal. Formulary 2002;37:389-399.
3.
Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, Kern WV, Marr KA, Ribaud P, Lortholary O, Sylvester R, Rubin RH, Wingard JR, Stark P, Durand C, Caillot D, Thiel E, Chandrasekar PH, Hodges MR, Schlamm HT, Troke PF, De Pauw B: Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347:408-415.
4.
Walsh TJ, Pappas P, Winston DJ, Lazarus HM, Petersen F, Raffalli J, Yanovich S, Stiff P, Greenberg R, Donowitz G, Schuster M, Reboli A, Wingard J, Arndt C, Reinhardt J, Hadley S, Finberg R, Laverdière M, Perfect J, Garber G, Fioritoni G, Anaissie E, Lee J: Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002;346:225-234.
5.
Kullberg BJ, Sobel JD, Ruhnke M, Pappas PG, Viscoli C, Rex JH, Cleary JD, Rubinstein E, Church LW, Brown JM, Schlamm HT, Oborska IT, Hilton F, Hodges MR: Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 2005;366:1435-1442.
6.
Birch DG: Surrogate electroretinographic markers for assessing therapeutic efficacy in the retina. Expert Rev Mol Diagn 2004;4:693-703.
7.
Zrenner E: The role of electrophysiology and psychophysics in ocular toxicology; in Fraunfelder FT, Fraunfelder WA, Chambers WA (eds): Clinical Ocular Toxicology. Philadelphia, Elsevier, 2008, pp 21-38.
8.
Pfizer Inc: FDA Antiviral Drugs Advisory Committee: briefing document for voriconazole (oral and intravenous formulations). 2001. www.fda.gov/ohrms/dockets/ac/01/briefing/3792b2_01_pfizer.pdf (accessed October 4, 2013).
9.
Marmor MF, Zrenner E: Standard for clinical electroretinography (1999 update). International Society for Clinical Electrophysiology of Vision. Doc Ophthalmol 1999;97:143-156.
10.
Mantyjarvi M: Normal test scores in the Farnsworth-Munsell 100 hue test. Doc Ophthalmol 2001;102:73-80.
11.
Park HJ, Kim DM, Youn DH, Hong C: Detection of early visual field change in ocular hypertension using STATPAC. Korean J Ophthalmol 1990;4:16-22.
12.
Hardy KJ, Craven B, Foster DH, Scarpello JH: Extent and duration of practice effects on performance with the Farnsworth-Munsell 100-hue test. Ophthalmic Physiol Opt 1994;14:306-309.
13.
Gouras P, MacKay CJ: Light adaptation of the electroretinogram. Diminished in retinitis pigmentosa. Invest Ophthalmol Vis Sci 1989;30:619-624.
14.
Sterling P, Matthews G: Structure and function of ribbon synapses. Trends Neurosci 2005;28:20-29.
15.
Banin E, Shalev RS, Obolensky A, Neis R, Chowers I, Gross-Tsur V: Retinal function abnormalities in patients treated with vigabatrin. Arch Ophthalmol 2003;121:811-816.
16.
Krauss GL, Johnson MA, Miller NR: Vigabatrin-associated retinal cone system dysfunction: electroretinogram and ophthalmologic findings. Neurology 1998;50:614-618.
17.
Zrenner E, Apfelstedt-Sylla E, Rüther K: Clinical aspects: retinitis pigmentosa; in Djamgoz MBA, Archer SN, Vallerga S (eds): Neurobiology and Clinical Aspects of the Outer Retina. London, Chapman & Hall, 1995, pp 447-460.
18.
Tan K, Brayshaw N, Tomaszewski K, Troke P, Wood N: Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities. J Clin Pharmacol 2006;46:235-243.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.